Toxicity of induction and consolidation treatments
| Toxicity . | WHO grade . | Patients with adverse events (%) . | |||
|---|---|---|---|---|---|
| Induction . | Consolidation . | ||||
| MOPP/ABV . | ABVPP . | Chemotherapy . | RTx . | ||
| Patients assessable | 208/2384-150 | 210/2464-150 | 150/1834-150 | 177 | |
| Neutropenia | 3-4 | 54 | 42 | 33 | 154-151 |
| Thrombocytopenia | 3-4 | 9 | 3 | 7 | 22 |
| Anemia | 3-4 | 11 | 2 | 4 | 3 |
| Infection | 1-2 | 22 | 21 | 10 | 9 |
| 3-4 | 10 | 7 | 2 | 1 | |
| Nausea/vomiting | 3-4 | 9 | 7 | 3 | 11 |
| Peripheral neuropathy | 1-2 | 24 | 11 | 10 | — |
| 3 | 2 | 1 | — | — | |
| Alopecia | 3-4 | 18 | 14 | — | — |
| Toxicity . | WHO grade . | Patients with adverse events (%) . | |||
|---|---|---|---|---|---|
| Induction . | Consolidation . | ||||
| MOPP/ABV . | ABVPP . | Chemotherapy . | RTx . | ||
| Patients assessable | 208/2384-150 | 210/2464-150 | 150/1834-150 | 177 | |
| Neutropenia | 3-4 | 54 | 42 | 33 | 154-151 |
| Thrombocytopenia | 3-4 | 9 | 3 | 7 | 22 |
| Anemia | 3-4 | 11 | 2 | 4 | 3 |
| Infection | 1-2 | 22 | 21 | 10 | 9 |
| 3-4 | 10 | 7 | 2 | 1 | |
| Nausea/vomiting | 3-4 | 9 | 7 | 3 | 11 |
| Peripheral neuropathy | 1-2 | 24 | 11 | 10 | — |
| 3 | 2 | 1 | — | — | |
| Alopecia | 3-4 | 18 | 14 | — | — |